Status:
COMPLETED
A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This 2-arm study evaluated the efficacy and safety of 2 different treatment schedules of oral Xeloda with intravenous (IV) Eloxatin (oxaliplatin) and IV bevacizumab (Avastin) as a first-line treatment...
Eligibility Criteria
Inclusion
- Metastatic or inoperable locally advanced colorectal cancer
- \>=1 measurable target lesion
Exclusion
- Previous systemic therapy for advanced or metastatic disease
- Previous treatment with bevacizumab
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
435 Patients enrolled
Trial Details
Trial ID
NCT00118755
Start Date
July 1 2005
Last Update
March 3 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.